(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure. (2) Consists of gain on sale of investments $16,400 and asset impairment charges ...

"Late-Stage Development first quarter revenues grew 16.8% year-on-year to $373 million. Central laboratories and clinical development grew 20% and 18%, respectively, which more than offset a decline ...